{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=VRC-HIVADV014-00-VP+placebo",
    "query": {
      "intervention": "VRC-HIVADV014-00-VP placebo"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 4,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-10-05T12:14:12.342Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01479296",
      "title": "Evaluating the Immune Response to a rAd5 HIV Vaccine Administered in Three Different Ways in Healthy, HIV-Uninfected Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "VRC rAd5 vaccine (rAd5 gag-pol/env A/B/C)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "rAd5 env A",
          "type": "BIOLOGICAL"
        },
        {
          "name": "rAd5 env B",
          "type": "BIOLOGICAL"
        },
        {
          "name": "rAd5 env C",
          "type": "BIOLOGICAL"
        },
        {
          "name": "rAd5 gag-pol",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo Vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 90,
      "start_date": "2011-12",
      "completion_date": "2017-11-27",
      "has_results": false,
      "last_update_posted_date": "2021-10-15",
      "last_synced_at": "2026-10-05T12:14:12.342Z",
      "location_count": 8,
      "location_summary": "San Francisco, California • Chicago, Illinois • Boston, Massachusetts + 4 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01479296"
    },
    {
      "nct_id": "NCT00091416",
      "title": "Safety of and Immune Response to an HIV-1 Vaccine Boost (VRC-HIVADV014-00-VP) in HIV Uninfected Adults Who Participated in HVTN 052",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "VRC-HIVADV014-00-VP",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 70,
      "start_date": null,
      "completion_date": "2006-05",
      "has_results": false,
      "last_update_posted_date": "2021-10-14",
      "last_synced_at": "2026-10-05T12:14:12.342Z",
      "location_count": 8,
      "location_summary": "Baltimore, Maryland • Boston, Massachusetts • St Louis, Missouri + 5 more",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Rochester",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00091416"
    },
    {
      "nct_id": "NCT00125970",
      "title": "HVTN Protocol 204 - A Phase II Clinical Trial to Evaluate the Safety and Immunogenicity of a Multiclade HIV-1 DNA Plasmid Vaccine, VRC-HIVDNA016-00-VP, Followed by a Multiclade Recombinant Adenoviral Vector HIV-1 Vaccine Boost, VRCHIVADV014-00-VP, in HIV-1 Uninfected Adult Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "VRC-HIVDNA016-00-VP",
          "type": "BIOLOGICAL"
        },
        {
          "name": "VRC-HIVADV014-00-VP",
          "type": "BIOLOGICAL"
        },
        {
          "name": "VRC-HIVDNA016-00-VP placebo",
          "type": "BIOLOGICAL"
        },
        {
          "name": "VRC-HIVADV014-00-VP placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 480,
      "start_date": "2005-09",
      "completion_date": "2010-01",
      "has_results": false,
      "last_update_posted_date": "2021-10-15",
      "last_synced_at": "2026-10-05T12:14:12.342Z",
      "location_count": 5,
      "location_summary": "Birmingham, Alabama • Baltimore, Maryland • Boston, Massachusetts + 2 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Providence",
          "state": "Rhode Island"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00125970"
    },
    {
      "nct_id": "NCT00865566",
      "title": "Safety and Effectiveness of HIV-1 DNA Plasmid Vaccine and HIV-1 Recombinant Adenoviral Vector Vaccine in HIV-Uninfected, Circumcised Men and Male-to-Female (MTF) Transgender Persons Who Have Sex With Men",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "DNA plasmid vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Recombinant adenoviral serotype 5 (rAD5) vector vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "DNA vaccine placebo",
          "type": "BIOLOGICAL"
        },
        {
          "name": "HIV-1 recombinant adenovirus vaccine placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "MALE",
        "summary": "18 Years to 50 Years · Male only"
      },
      "enrollment_count": 2504,
      "start_date": "2009-05",
      "completion_date": "2017-10-06",
      "has_results": true,
      "last_update_posted_date": "2021-10-15",
      "last_synced_at": "2026-10-05T12:14:12.342Z",
      "location_count": 22,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • San Francisco, California + 15 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00865566"
    }
  ]
}